LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container patents expire, and when can generic versions of Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container launch?

Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container is a drug marketed by Abbott and Hospira and is included in two NDAs.

The generic ingredient in LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container

A generic version of LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as lidocaine hydrochloride by PHARMOBEDIENT on November 18^th, 1982.

Summary for LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	2,146
DailyMed Link:	LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	PHASE4
Assiut University	NA
Sakarya University	NA

See all LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER	lidocaine hydrochloride	INJECTABLE;INJECTION	018954-001	Jul 9, 1985		DISCN	No	No
Hospira	LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER	lidocaine hydrochloride	INJECTABLE;INJECTION	018388-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Overview and Financial Trajectory for Lidocaine Hydrochloride 0.2% in Dextrose 5% in Plastic Container

Last updated: February 15, 2026

Lidocaine Hydrochloride 0.2% in Dextrose 5% in a plastic container is an injectable local anesthetic solution primarily used in hospitals and outpatient clinics for anesthesia and pain management. The product features a standard concentration suitable for infiltration anesthesia and nerve blocks. The market's dynamics hinge on factors like generics competition, regulatory pathways, and usage trends in surgical procedures.

---

Key Market Drivers

• Increasing demand for local anesthetics: The rise in minimally invasive surgeries boosts the need for local anesthetics, including lidocaine solutions.
• High adoption in hospital settings: Preference for prefilled plastic containers improves convenience, reduces contamination risks, and aligns with safety regulations.
• Growing outpatient procedures: The shift toward outpatient surgeries increases the volume of anesthetic solutions required.

Market Size and Revenue Potential

Current Market Scope

Estimated global sales of lidocaine solutions for injectable use exceeded USD 1.1 billion in 2022, with a compound annual growth rate (CAGR) of approximately 3-4% projected through 2027 [1].

Segment Breakdown

Segment	Market Share	Notes
Generic lidocaine solutions	~75%	Dominates due to patent expirations, low entry barriers
Branded formulations	~15%	Limited due to patent expiries, higher pricing
Specialty formulations	~10%	Includes preservative-free and pediatric formulations

The specific formulation—0.2% lidocaine in dextrose 5%—represents a subset within this market, primarily for hospital and clinic use.

Pricing Trends

• Unit price: Cost per 10 mL vial ranges from USD 0.50 to USD 1.20, depending on regional healthcare pricing policies.
• Pricing pressure: Increased competition from generics exerts downward pressure on prices, especially in North America and Europe.

Regulatory and Patent Considerations

• Patent expirations: Most lidocaine formulations have expired patents, opening markets for generics since the early 2000s.
• Regulatory approvals: Both FDA and EMA approvals favor standard formulations; innovator companies or new entrants must demonstrate bioequivalence for market entry.
• Manufacturing standards: Good Manufacturing Practice (GMP) compliance influences market access, especially in high-regulation regions.

---

Competitive Landscape

Company	Estimated Market Share	Key Product Features
Hospira (Pfizer)	Largest	Cost-effective, widely used
Fresenius Kabi	Significant	Focus on hospital-grade products
Sagent Pharma	Niche	Specialty formulations, preservative-free
Generic manufacturers	Dominant	Numerous local and international players

Private-label or regional manufacturers also contribute at lower price points, influencing market pricing.

Emerging Trends and Innovation

• Pre-filled syringes vs. vials: Growing preference for pre-filled plastic syringes enhances safety and makes administration easier.
• Combination products: Development of lidocaine with adjunct agents for enhanced anesthesia effects.
• Alternative preservatives: Shift towards preservative-free formulations to accommodate sensitive patient populations.

---

Future Market Projections

Predicted annual revenue growth remains stable at 3-4% through 2027, driven by:

• Broader adoption in outpatient and ambulatory surgery centers.
• Increased global healthcare expenditure.
• Expansion into emerging markets; especially APAC where healthcare infrastructure improves rapidly.

In markets like China and India, low-cost generics will dominate, with potential for incremental growth as healthcare access expands.

---

Risks and Challenges

• Pricing pressure: Heightened competition reduces margins.
• Regulatory hurdles: Increasing scrutiny on preservative-free solutions or new formulations.
• Supply chain disruptions: Raw material shortages or manufacturing bottlenecks can impact availability and profitability.

---

Key Takeaways

• The market for lidocaine 0.2% in dextrose 5% in plastic containers remains stable, with growth driven by procedural demand and shift toward outpatient care.
• Generics dominate the landscape, exerting price competition pressure.
• Product differentiation through prefilled syringes and preservative-free options influences market dynamics.
• Future growth prospects hinge on expanding to emerging markets and developing innovative formulations.
• Regulatory factors favor standardized, bioequivalent solutions with strict GMP adherence.

---

Frequently Asked Questions

1. What regions present the highest growth opportunities?
Emerging markets such as China, India, and Southeast Asia see significant growth due to expanding healthcare infrastructure and increased outpatient procedures.

2. How does patent status influence market competition?
Patent expirations have resulted in a proliferation of generic manufacturers, reducing prices and increasing accessibility.

3. What are the main risks for manufacturers in this market?
Pricing erosion, regulatory compliance, and supply chain disruptions are primary risks impacting profitability.

4. How does the shift toward prefilled syringes affect the market?
Prefilled syringe formulations are preferred for their safety, ease of administration, and reduced contamination risk, leading to higher adoption rates.

5. Are brand-name lidocaine products maintaining market share?
Brand-name products hold limited market share due to patent expiry and the prevalence of cost-driven generic competition.

---

References

[1] Brightfield Group. "Global Local Anesthetics Market Report," 2022.